Medication vs Medication
Wegovy vs Saxenda
A practical UK comparison focused on what is genuinely different — not which brand has the loudest marketing.
Wegovy injection
STEP 1: mean -14.9% at 68 weeks with 2.4 mg; 7.2 mg is now a licensed maintenance option for adults with obesity if needed
Liraglutide (Saxenda / licensed equivalents)
Large adult trial: mean -8.0% at 56 weeks vs -2.6% placebo
Side-by-side
| Wegovy injection | Liraglutide (Saxenda / licensed equivalents) | |
|---|---|---|
| Active ingredient | semaglutide | liraglutide |
| Form | Weekly injection | Daily injection |
| Frequency | Once weekly | Once daily |
| Licence | UK weight management licence | UK weight management licence |
| NHS context | NICE-recommended in specialist weight-management pathways; access depends on pathway | NICE option in specialist services for defined groups; pathway availability varies |
| Evidence | Very strong | Mature |
| Weight-loss evidence | STEP 1: mean -14.9% at 68 weeks with 2.4 mg; 7.2 mg is now a licensed maintenance option for adults with obesity if needed | Large adult trial: mean -8.0% at 56 weeks vs -2.6% placebo |
| Maintenance | Long-term support/treatment matters; weight regain after stopping has been demonstrated | Ongoing treatment and maintenance strategy matter |
| GI considerations | Common GI effects; dose escalation is used to improve tolerability | GI effects common; daily dosing can add burden |
Reasons to discuss Wegovy injection
- Large evidence base
- Weekly dosing
- Cardiovascular outcome evidence in appropriate populations
- 2.4 mg established; 7.2 mg injectable option now licensed for adults with obesity if needed
Trade-offs
- Injection
- GI effects
- The new 7.2 mg option should not be compared using old 2.4 mg-only trial assumptions
- NHS access remains pathway-limited
Reasons to discuss Liraglutide (Saxenda / licensed equivalents)
- Longer track record in obesity treatment
- GLP-1 mechanism
- Can be appropriate where other options are unsuitable
- Licensed specifically for weight management
Trade-offs
- Daily injection
- Lower average weight loss than newer weekly incretin treatments
- NHS use is restricted
- Daily adherence burden
Which is stronger for weight loss?
Wegovy injection is rated 8/10 and Liraglutide (Saxenda / licensed equivalents) 5/10 in our comparison framework. That rating summarises the obesity evidence available for the licensed formulation; it is not a prediction of your result.
Which is easier to live with?
Wegovy injection: Once weekly. Liraglutide (Saxenda / licensed equivalents): Once daily. For some people a weekly injection is easier than a daily tablet; for others avoiding a needle is decisive.
NHS vs private reality
NICE-recommended in specialist weight-management pathways; access depends on pathway. NICE option in specialist services for defined groups; pathway availability varies. NICE criteria and NHS availability are related but not identical, so check the current pathway rather than assuming a clinically eligible medicine is immediately available through a GP.
Maintenance matters
Long-term support/treatment matters; weight regain after stopping has been demonstrated. Ongoing treatment and maintenance strategy matter. A treatment comparison that ends at the point of weight loss is incomplete.
Questions to ask a prescriber
- Which option is actually licensed and clinically appropriate for my health history?
- How do the expected benefits compare for someone with my diabetes/cardiovascular history?
- What side effects should make me contact you?
- What will monitoring involve?
- What is the plan if I cannot tolerate the maintenance dose?
- What happens if I stop?
Sources
Continue exploring